GSK-205715

Study Sponsor: GSK

Study Title

A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled asthma

Medicine or Vaccine (generic name)

fluticasone furoate/vilanterol/umeclidinium bromide

Sponsor Identification Number

205715

Trial Registry Identification Number(#'s)

NCT02924688 2016-001304-37

Medical Condition

Asthma

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=205715

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT02924688

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-001304-37

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This study can only be requested for research into the original disease or medicine studied due to restrictions in the patient informed consent. This study is available in CDISC format.

Date Added to this Site

January 2021